Circulating tumor DNA may guide immunotherapy use in limited-stage SCLC, new study shows - EurekAlert!
Tarlatamab with anti-PD-L1 as first-line maintenance after chemo-immunotherapy for ES-SCLC demonstrates acceptable safety profile and unprecedented overall survival - EurekAlert!
Precision medicine in SCLC: DLL3, ASC1, TTF-1, and Ki-67 expression - EurekAlert
